1 2 6 9 9 9 4 1/2/03 EPO 02 0 7 4 2 0 0 9/26/02 WO 97 0 4 1 8 9 6 11/13/97 WO 00 0 7 2 8 4 7 12/7/00 WO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) DAVID G et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitatic associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vol. 155, no. 2, May 2001 YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560 67, December 1998	INFORMA	TION DIS	CLOS	URE CIT	FATION	AT	TY. DOC	KET N	O. PC2507	71A	SEF	RIAL NO	O. 10/6	599,77	'8
U.S. PATENT DOCUMENTS DATE NAME CLASS SUBCLASS PATENT NUMBER DATE NAME CLASS SUBCLASS PATENT NUMBER COUNTRY CLASS SUBCLASS PATENT NUMBER DATE COUNTRY CLASS SUBCLASS PATENT NUMBER PATENT NUMBER NUMBER NUMBER N	(Use several spaces of newssary)					AP	PLICAN	T Jay	ymin C. Sh	nah					
DATE NAME CLASS SUBCLASS PANDERNITION. FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS PANDERNITION COUNTRY CLASS SUBCLASS PANDERNITION DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS PANDERNITION CLASS SUBCLASS PANDERNIERNIERNITION CLASS SUBCLASS PANDERNIERNIERNIERNITION CLASS SUBCLASS PANDERNIERNIERNIERNIERNIERNIERNIERNIERNIERNI	(3)				FIL	FILING DATE October 21, 2003					GROUP 1614				
FOREIGN PATENT DOCUMENTS DATE COUNTRY CLASS SUBCLASS TIMES TYPES					<u> </u>		PATENT	DOCU	MENTS						
FOREIGN PATENT DOCUMENTS DATE COUNTRY CLASS SUBCLASS TIMES TYPES		6		000	SKENT NUME	3ER			DATE	NAME		CLASS	SUBCLASS	I E	
DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TWMSA.T YES 1 2 6 9 9 9 4 1/2/03 EPO 02 0 7 4 2 0 0 9/28/02 WO 97 0 4 1 8 9 6 11/13/97 WO 00 0 7 2 8 4 7 12/7/00 WO DAVID G et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitatic associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vo. 155, no. 2, May 2001 YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560 67, December 1998 A. HATEFI AND B. AMSDEN, "Biodegradable injectable in situ forming drug deliver systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002 YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA			F2 ~	3	2	3	0	4	11/5/98	Yesook Kim e	at al.				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) DAVID G et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitatic associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vo. 155, no. 2, May 2001 YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560 67, December 1998 A. HATEFI AND B. AMSDEN, "Biodegradable injectable in situ forming drug deliver systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002 YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA					FO	REIG	N PATE	NT DO	CUMENTS	\$					
1 2 6 9 9 9 4 1/2/03 EPO 02 0 7 4 2 0 0 9/26/02 WO 97 0 4 1 8 9 6 11/13/97 WO 00 0 7 2 8 4 7 12/7/00 WO DAVID G et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitatic associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vol. 155, no. 2, May 2001 YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560-67, December 1998 A. HATEFI AND B. AMSDEN, "Biodegradable injectable in situ forming drug deliver systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002 YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA	1		DOG	CUMENT NU	MBER				DATE	COUNTRY		CLASS	SUBCLASS	\vdash	NOTA NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) DAVID G et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitatic associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vol. 155, no. 2, May 2001 YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560 67, December 1998 A. HATEFI AND B. AMSDEN, "Biodegradable injectable in situ forming drug deliver systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002 YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA	th	1	2	6	9	9	9	4	1/2/03	EPO				163	NU
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) DAVID G et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitatic associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vo. 155, no. 2, May 2001 YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560 67, December 1998 A. HATEFI AND B. AMSDEN, "Biodegradable injectable in situ forming drug deliver systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002 YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA	$\Delta A = 0$	02	0_	7	4	2	0	0	9/26/02	wo		\perp			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) DAVID G et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitatic associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vo. 155, no. 2, May 2001 YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560 67, December 1998 A. HATEFI AND B. AMSDEN, "Biodegradable injectable in situ forming drug deliver systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002 YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA		97	0	4	1	8	9	6	11/13/97	wo					
DAVID G et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitatic associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vo. 155, no. 2, May 2001 YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560 67, December 1998 A. HATEFI AND B. AMSDEN, "Biodegradable injectable in situ forming drug deliver systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002 YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA	HN	00	0	7	2	8	4	7	12/7/00	wo					
DAVID G et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitatic associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vo. 155, no. 2, May 2001 YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560 67, December 1998 A. HATEFI AND B. AMSDEN, "Biodegradable injectable in situ forming drug deliver systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002 YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA															
DAVID G et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitatic associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vo. 155, no. 2, May 2001 YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560 67, December 1998 A. HATEFI AND B. AMSDEN, "Biodegradable injectable in situ forming drug deliver systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002 YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA															
DAVID G et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitatic associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vo. 155, no. 2, May 2001 YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560 67, December 1998 A. HATEFI AND B. AMSDEN, "Biodegradable injectable in situ forming drug deliver systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002 YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA		 			 									<u> </u>	
DAVID G et al., "Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitatic associated with psychosis: A double-blind, randomized trial" PSYCHOPHARMACOLOGY vo. 155, no. 2, May 2001 YESOOK KIM et al., "Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560 67, December 1998 A. HATEFI AND B. AMSDEN, "Biodegradable injectable in situ forming drug deliver systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002 YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA		<u> </u>	OTHE	P DOCI	IMENTS	/Incl	iding Au	thor Tit	lo Data 5	Parlinant Page		<u> </u>	l		
sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560 67, December 1998 A. HATEFI AND B. AMSDEN, "Biodegradable injectable in situ forming drug deliver systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002 YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA	#N	asso	ciated	with ps	ychosis	cular : A do	(IM) zip ouble-bl	rasidoi ind, rar	ne 20 mg ndomized	is effective trial" PSYC	in re HOP	ducing	acute a	igitatio	on ol.
systems" JOURNAL OF CONTROLLED RELEASE vol. 80, pages 9-28, 2002 YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA	th/	sulfobutyl ether" JOURNAL OF PHARMACEUTICAL SCIENCES vol. 87, no. 12, pages 1560-													
YIE W. CHIEN, "Long-acting parenteral drug formulations" JOURNAL OF PARENTERA SCIENCE & TECHNOLOGY, vol. 35, No. 3, May-June 1981	M	A. HATEFI AND B. AMSDEN, "Biodegradable injectable in situ forming drug delivery													
	N	YIE SCIE	W. CH	IIEN, "	Long-ad	ting 3Y, vo	parente ol. 35, N	ral dru lo. 3, M	g formula lay-June	ations" JOU 1981	IRNA	L OF	PAREN	ITER/	۹L
AMINER DATE CONSIDERED 10 / 10 / 10	AMINER	$\frac{1}{2}$		- .	-		· · · · · · · · · · · · · · · · · · ·	DATE C	ONSIDERE) 1.	/.	,			
muyen (0/13/19		M	m	en	2	_/	/			0')	11	<u>/ د</u>	19.		
AMINER: Initial if reference considered, whether or not citation is in coordinance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form next communication to applicant.	AMINER: Initial if next communica	reference cons tion to applican	idered, vnet t.	ner or not cita	ation is in coof	rmance	with MPEP 60	9; Draw line	through citation i	if not in conformance a	and not o	considered.	Include copy of	this form	
orms with FORM PTO-FB-A820 INFORMATION DISCI	orms with FORM	PTO-FB-A820	 .		- ()			*					INFORMA	TION DISC	LOS



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known			
		_		Application Number	10/699,778-Conf. #005905		
11	NFORMATION	N DI	SCLOSURE	Filing Date	November 4, 2003		
S	TATEMENT	BY /	APPLICANT	First Named Inventor	Churl Woo CHOI		
				Art Unit	2871		
(Use as many sheets as necessary)				Examiner Name	H.L. Ngo		
Sheet	heet 1 of 1		Attorney Docket Number	0465-1069P			

U.S. PATENT DOCUMENTS								
Examiner Initials* Cite No.¹ Number-Kind Code² (if known) Document Number Publication Date Name of Patentee or Applicant of Cited Document Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Relevant Passages or R Figures Appear								
				•				

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
THE LAND	ВА	TW-461686-B1	10-21-2001						
140	BB	TW-493781-Y	07-01-2002						

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	r					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	home		Date Considered	10/15/06
Birch, Stewart, Kolasc	th & Birch, LLP	- J		J/E/src

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.